Dermatologic Therapy最新文献

{"title":"Therapeutic Use of Cold Atmospheric Plasma for the Treatment of Mild Acne Papulopustulosa—A Randomized, Controlled, Double-Blind Pilot Study","authors":"Melvin Bae,&nbsp;Jürgen Lademann,&nbsp;Martina C. Meinke,&nbsp;Björn Meder,&nbsp;Christoph Geilen","doi":"10.1155/dth/4228323","DOIUrl":"https://doi.org/10.1155/dth/4228323","url":null,"abstract":"<div>\u0000 <p>Acne is a common disease worldwide, predominantly occurring in teenagers. Commonly prescribed therapies often cause adverse effects and in case of antibiotics bare the risk of developing resistances. Cold atmospheric plasma (CAP) is a well-tolerable, physical treatment method, which is well established in the treatment of chronic wounds since it provides bactericidal and wound healing properties. Our aim was to evaluate the efficacy and safety of CAP as a potential add-on therapy for mild acne papulopustulosa in a randomized controlled, double-blind pilot study. Forty participants were randomized into two arms of 20 each. Both groups self-applied 0.1% of adapalene cream daily and received weekly skin-cleansing by a physician combined with either CAP verum-device treatments or placebo-device applications instead. The endpoint of the treatment segment was at 6, and follow-up was at 10 weeks. The co-primary endpoints total inflammatory lesion count (TILC) and acne-specific Investigator Global Assessment (IGA) score as well as secondary endpoints sebumetry, total porphyrin count (TPC) reflecting <i>Cutibacterium acnes</i> colonization, and occurrence of adverse events (AEs) were measured from baseline until follow-up, while the Acne-specific Quality of Life (AQOL) questionnaire was assessed at baseline and endpoint. TILC decreased greater in the verum versus control group from baseline (45.8 vs. 49.4) toward endpoint (22.1 vs. 38.6; <i>p</i> = 0.07) to follow-up (16.5 vs. 28.7; <i>p</i> = 0.48), matched by the IGA score with similarly greater improvement in the verum versus control group from baseline (2.3 vs. 2.6) to endpoint (1.3 vs. 2.3; <i>p</i> &lt;  0.001) until follow-up (1.0 vs. 1.9; <i>p</i> = 0.006). Sebumetry, TPC, and AQOL scores decreased more during treatment and in the verum group. AE occurred less frequently in the verum group without serious AE reported overall (all <i>p</i> &lt; 0.05). Conclusively, CAP proved to be an efficient and well-tolerable add-on therapy for the treatment of mild acne papulopustulosa.</p>\u0000 <p><b>Trial Registration:</b> German Registry of Clinical Trials: DRKS00032416</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4228323","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143535885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Retrospective Study to Investigate Safety of Receiving Interleukin-17 Monoclonal Antibody for Psoriasis Patients With Hepatitis B Virus","authors":"Haohao Wu,&nbsp;Juan Wang,&nbsp;Min Zhang,&nbsp;Jing Peng,&nbsp;Yi You","doi":"10.1155/dth/8942831","DOIUrl":"https://doi.org/10.1155/dth/8942831","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The increasing utilization of interleukin-17 (IL-17) monoclonal antibody (MA) for psoriasis treatment, coupled with the high prevalence of hepatitis B virus (HBV), underscores the need for comprehensive safety data. This retrospective study aims to evaluate the safety of IL-17 MA treatment in psoriasis patients with concurrent HBV infection.</p>\u0000 <p><b>Research Design and Methods:</b> The study screened 531 psoriasis patients treated with IL-17 MA, ultimately enrolling 59 patients with abnormal HBV serological data. Outcomes assessed include HBV virological reactivation and changes in HBsAb serum quantification post-IL-17 MA therapy.</p>\u0000 <p><b>Results:</b> Laboratory data revealed HBV virological reactivation in two psoriasis patients classified as inactive HBV carriers (IBCs). Patients who had previously received HBV vaccination exhibited a significant decrease in HBsAb serum quantification following IL-17 MA therapy.</p>\u0000 <p><b>Conclusion:</b> IL-17 MA therapy presents a potential risk of HBV reactivation in psoriasis patients with HBV infection. Furthermore, IL-17 MA appears to weaken HBV resistance in vaccinated patients.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8942831","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Clinical Study of Laser vs. Cryotherapy in Plantar Warts: Effectiveness and Safety","authors":"Giuliana Secolo,&nbsp;Innocenzo Salvatore Secolo,&nbsp;Nadia Fernández-Ehrling,&nbsp;Juan Vicente-Mampel,&nbsp;Raul Gallego-Estévez,&nbsp;Javier Ferrer-Torregrosa","doi":"10.1155/dth/7793571","DOIUrl":"https://doi.org/10.1155/dth/7793571","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Plantar warts are common skin lesions caused by HPV that can generate discomfort and impact quality of life. There are several therapeutic options such as cryotherapy or laser, but more high-quality comparative studies are needed.</p>\u0000 <p><b>Methods:</b> A randomized clinical trial was performed with 44 patients with plantar warts who were assigned 22 to each group. Sessions were applied at 1-week intervals evaluating clinical healing, VAS pain scale, and complications.</p>\u0000 <p><b>Results:</b> Laser removed warts in significantly fewer sessions (mean 3.26) than cryotherapy (mean 4.06) (<i>p</i> = 0.022). There were no differences in safety or pain between groups.</p>\u0000 <p><b>Conclusion:</b> Diode laser demonstrated faster removal of plantar warts than cryotherapy, constituting a promising noninvasive alternative. Further studies are needed to confirm its long-term efficacy and safety profile.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT06228521</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7793571","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143489739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EASI 100 as a Therapeutic Target in Pediatric Atopic Dermatitis","authors":"João Teixeira,&nbsp;André Aparício-Martins,&nbsp;Mariana Pedroso,&nbsp;Carolina Figueiredo,&nbsp;Felicidade Santiago,&nbsp;Mariana Batista,&nbsp;Margarida Gonçalo,&nbsp;Leonor Ramos","doi":"10.1155/dth/1380954","DOIUrl":"https://doi.org/10.1155/dth/1380954","url":null,"abstract":"<div>\u0000 <p>Dupilumab, a monoclonal antibody targeting interleukin-4 receptor alpha, has shown both robust efficacy and safety in pediatric atopic dermatitis (AD), but data on complete disease control (Eczema Area and Severity Index [EASI] 100) are scarce. A retrospective analysis of 25 pediatric patients at our institution with a median treatment duration of 20 months revealed a significant improvement in EASI scores, with 44.0% achieving EASI 100 at a median of 52 weeks of treatment. No significant differences were found between the group of patients achieving EASI 100 and those who did not. While this study provides additional insight into the efficacy and safety of dupilumab in pediatric AD, its limited sample size underscores the need for larger scale studies focusing on EASI 100 to better understand the factors influencing complete disease control and to optimize treatment strategies for pediatric patients with AD.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1380954","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Dose Oral Minoxidil in Lichen Planopilaris: Efficacy and Safety","authors":"Mina Saber,&nbsp;Shaghayegh Dehghani,&nbsp;Farahnaz Fatemi Naeini,&nbsp;Fatemeh Mohaghegh","doi":"10.1155/dth/1323718","DOIUrl":"https://doi.org/10.1155/dth/1323718","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Treating lichen planopilaris (LPP) is challenging for dermatologists. Along with anti-inflammatory agents, another goal of treatment is to improve hair thickness in unaffected areas to cover the scars.</p>\u0000 <p><b>Aim:</b> To evaluate the effectiveness and safety of adding low-dose oral minoxidil (OM) to the standard anti-inflammatory treatment of LPP.</p>\u0000 <p><b>Method:</b> A total of 37 patients with LPP were randomly assigned to receive either 15 mg/week methotrexate (MTX) plus topical clobetasol or 1 mg/day minoxidil in addition to MTX plus clobetasol for 6 months. The Lichen Planopilaris Activity Index (LPPAI), dermoscopy, and standard photography evaluated the treatment efficacy.</p>\u0000 <p><b>Results:</b> Both groups exhibited a significant improvement in LPPAI (<i>p</i> &lt; 0.001). The following signs/symptoms demonstrated notable improvements in frequency and/or severity in both groups: pruritus, anagen pull test, follicular prominency, scalp erythema, perifollicular erythema, milky red area, and pigmentation. However, pain, burning sensation, hair tufting, and spreading only improved in the MTX + low-dose OM group. Elongated blood vessels did not improve in either group. In terms of hair thickness and density, there was no significant difference between the two groups.</p>\u0000 <p><b>Conclusion:</b> The addition of 1 mg/day minoxidil to the standard treatment of LPP was found to be safe but did not yield significant effects on LPPAI and hair density/thickness. Notably, two patients who received low-dose OM (2/19, 10.5%) showed hair regrowth in scarring areas. Trials with higher doses of minoxidil may be promising.</p>\u0000 <p><b>Trial Registration:</b> Iranian Registry of Clinical Trials: IRCT20220528055005N1</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1323718","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Dietary Intake With the Risk of Atopic Diseases: A Mendelian Randomization Study","authors":"Xixia Dai,&nbsp;Li Lei,&nbsp;Ling Jiang,&nbsp;Yibo Hu,&nbsp;Songjiang Wu,&nbsp;Menglu Chen,&nbsp;Yixuan Liang,&nbsp;Jing Chen,&nbsp;Chuhan Fu,&nbsp;Qinghai Zeng","doi":"10.1155/dth/9913983","DOIUrl":"https://doi.org/10.1155/dth/9913983","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Previous observational studies have shown an association between specific dietary intake and atopic diseases. However, few studies have analyzed the causal effects of dietary factors on risk of atopic diseases. Therefore, we conducted a Mendelian randomization (MR) study to explore these relationships.</p>\u0000 <p><b>Methods:</b> In this study, we obtained summary statistics on dietary intake and atopic diseases including atopic dermatitis, allergic asthma, allergic conjunctivitis, and allergic rhinitis from large genome-wide association studies (GWASs) in European populations. MR analysis was performed using the inverse variance weighted (IVW) method, supplemented with MR Egger, weighted median, maximum likelihood, and weighted model analysis methods.</p>\u0000 <p><b>Results:</b> Our study included 34 diet-related exposure factors. The results indicated that increased intake of filtered coffee could reduce the risk of developing atopic dermatitis. Conversely, higher average monthly intake of other alcoholic drinks was associated with an increased risk of atopic dermatitis. For allergic asthma, higher intake of filtered coffee was identified as a protective factor, while increased average weekly intake of spirits and cherry were considered risk factors. Furthermore, an increase in average weekly intake of beer plus cider was found to potentially lower the risk of allergic conjunctivitis. However, we did not discover any causal association between the risk of allergic rhinitis and the dietary intake factors.</p>\u0000 <p><b>Conclusion:</b> This MR study validates the potential causal effects of specific dietary intake on different atopic diseases and provides strong support for the development of individualized prevention strategies and health interventions at the family level.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9913983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143380506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Noncoding RNAs in Atopic Dermatitis: Insight Into Inflammation and Immune Regulation","authors":"Lemei Zhu,&nbsp;Yuqing Liu,&nbsp;Zhuo Gong,&nbsp;Bohua Zhu,&nbsp;Chenghao Zhang,&nbsp;Haoqi Zhang,&nbsp;Wei Liu,&nbsp;Shan Hui,&nbsp;Shuangni Duan,&nbsp;Pingping Bing","doi":"10.1155/dth/5568546","DOIUrl":"https://doi.org/10.1155/dth/5568546","url":null,"abstract":"<div>\u0000 <p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting approximately 20% of children and 10% of adults. While previous studies have linked AD to allergen exposure, disruption of the skin barrier, and Type 2 immune responses, the precise pathophysiology of AD remains elusive, significantly limiting the effectiveness of current treatments. Noncoding RNAs (ncRNAs), a diverse group of transcripts that do not encode proteins and account for at least 98% of the human genome, are implicated in numerous physiological and pathological processes. A growing body of evidence underscores the pivotal role of ncRNAs in the pathogenesis and progression of AD. This review offers a detailed synthesis of the latest insights into the involvement of ncRNAs in AD, as well as their potential as diagnostic biomarkers and therapeutic targets.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5568546","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imbalance of Endogenous Opioids and Its Association With Pruritus Among Renal Transplant Recipients: A Cross-Sectional Study","authors":"Piotr K. Krajewski,&nbsp;Aleksandra Sójka,&nbsp;Kinga Tyczyńska,&nbsp;Piotr Olczyk,&nbsp;Danuta Nowicka-Suszko,&nbsp;Magdalena Krajewska,&nbsp;Jacek C. Szepietowski","doi":"10.1155/dth/1915135","DOIUrl":"https://doi.org/10.1155/dth/1915135","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Chronic pruritus (CP) is a common and distressing symptom among renal transplant recipients (RTRs), yet its pathogenesis remains poorly understood. Recent evidence suggests that dysregulation of the endogenous opioid system may contribute to pruritus in various conditions, but its role in RTRs has not been thoroughly investigated.</p>\u0000 <p><b>Objective:</b> This study aimed to assess the concentrations of specific endogenous opioids (<i>β</i>-endorphin, dynorphin A, met-enkephalin, and leu-enkephalin) in RTRs with and without pruritus to explore their potential role in pruritus pathogenesis.</p>\u0000 <p><b>Methods:</b> A total of 129 RTRs and 47 healthy controls were included in the study. Serum levels of <i>β</i>-endorphin, dynorphin A, met-enkephalin, and leu-enkephalin were measured using enzyme-linked immunosorbent assays (ELISAs). Pruritus severity was assessed using the Worst Pruritus Numerical Rating Scale (WP-NRS) and the 4-Item Itch Questionnaire (4IIQ).</p>\u0000 <p><b>Results:</b> Pruritic RTRs had significantly lower serum <i>β</i>-endorphin levels compared to nonpruritic RTRs (<i>p</i> = 0.008). However, there were no significant differences in dynorphin A, met-enkephalin, or leu-enkephalin levels between pruritic and nonpruritic RTRs or between RTRs and healthy controls. The <i>β</i>-endorphin to dynorphin A ratio also did not differ significantly between groups.</p>\u0000 <p><b>Conclusion:</b> The study suggests that disturbances in the endogenous opioid system, particularly involving <i>β</i>-endorphin, may play a role in the pathogenesis of pruritus in RTRs. Further research is needed to elucidate the precise mechanisms and to explore potential therapeutic interventions targeting the opioid system in this population.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1915135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143120475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intradermal Botulinum Toxin A for Melasma: A Randomized Split-Face Study Trial and In Vitro Study of Its Antimelanogenic Effect","authors":"Wilai Thanasarnaksorn,&nbsp;Thanan Supasiri,&nbsp;Uraiwan Panich,&nbsp;Saowalak Thanachaiphiwat,&nbsp;Nuntida Salakshna","doi":"10.1155/dth/5550483","DOIUrl":"https://doi.org/10.1155/dth/5550483","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Melasma is a challenging hyperpigmentation disorder without absolute treatment.</p>\u0000 <p><b>Aims:</b> This study aimed to evaluate the effects of intradermal botulinum toxin A (BoNT-A) on melasma and the protective effects of BoNT-A on UVA-induced melanogenesis in B16F10 melanoma cells.</p>\u0000 <p><b>Patients/Methods:</b> This study is a split-face randomized, double-blind, placebo-controlled trial in 12 melasma patients who received intradermal abobotulinumtoxinA injection into melasma lesions. An <i>in vitro</i> study was also conducted in B16F10 melanoma cells treated with different concentrations of BoNT-A prior to exposure to UVA. Cell viability and cellular melanogenesis were determined.</p>\u0000 <p><b>Results:</b> The adjusted MASI scores on the BoNT-A side were significantly lower than the control at 3 months after injection, 2.8 versus 4.5 (<i>p</i> &lt; 0.001), respectively. BoNT-A injection significantly reduced the MASI score at 2 and 3 months compared with the baseline of 4.1–3.2 (22%) (<i>p</i> &lt; 0.001) and 2.8 (31.7%) (<i>p</i> &lt; 0.001), respectively. Melanin content and tyrosinase activity in B16F10 cells with or without UVA irradiation were significantly reduced by treatment with BoNT-A in a dose-dependent manner without causing cytotoxicity.</p>\u0000 <p><b>Conclusions:</b> BoNT-A has a potentially beneficial effect in the treatment of melasma due to its antimelanogenic effect.</p>\u0000 <p><b>Trial Registration:</b> Clinical Trial Registry identifier: TCTR20250118001</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5550483","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143117851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep Learning Algorithms for Assessment of Post-Thyroidectomy Scar Subtype","authors":"Yuseong Chu,&nbsp;Seung-Won Jung,&nbsp;Solam Lee,&nbsp;Sang Gyun Lee,&nbsp;Yeon-Woo Heo,&nbsp;Sang-Hoon Lee,&nbsp;Hang-Seok Chang,&nbsp;Yong Sang Lee,&nbsp;Seok-Mo Kim,&nbsp;Sang Eun Lee,&nbsp;Byungho Oh,&nbsp;Mi Ryung Roh,&nbsp;Sejung Yang","doi":"10.1155/dth/4636142","DOIUrl":"https://doi.org/10.1155/dth/4636142","url":null,"abstract":"<div>\u0000 <p>The rising incidence of thyroid cancer globally is increasing the number of thyroidectomies, causing visible scars that can greatly affect the quality of life due to cosmetic, psychological, and social impacts. In this study, we explored the application of deep learning algorithms to objectively assess post-thyroidectomy scar morphology using computer-aided diagnosis. This study was approved by the Institutional Review Board of Yonsei University College of Medicine (approval no. 3-2021-051). A dataset comprising 7524 clinical photographs from 3565 patients with post-thyroidectomy scars was utilized. We developed a deep learning model using a convolutional neural network (CNN), specifically the ResNet 50 model and introduced a multiple clinical photography learning (MCPL) method. The MCPL method aimed to enhance the model’s understanding by considering characteristics from multiple images of the same lesion per patient. The primary outcome, measured by the area under the receiver operating characteristic curve (AUROC), demonstrated the superior performance of the MCPL model in classifying scar subtypes compared to a baseline model. Confidence variation analysis showed reduced discrepancies in the MCPL model, emphasizing its robustness. Furthermore, we conducted a decision study involving five physicians to evaluate the MCPL model’s impact on diagnostic accuracy and agreement. Results of the decision study indicated enhanced accuracy and reliability in scar subtype determination when the confidence scores of the MCPL model were integrated into decision-making. Our findings suggest that deep learning, particularly the MCPL method, is an effective and reliable tool for objectively classifying post-thyroidectomy scar subtypes. This approach holds promise for assisting professionals in improving diagnostic precision, aiding therapeutic planning, and ultimately enhancing patient outcomes in the management of post-thyroidectomy scars.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/4636142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143114119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}